The clot-busting drug tissue plasminogen activator (tPA) is currently the only FDA-approved therapy for acute stroke. However, increasing evidence suggests that tPA can also contribute to excitotoxic ...
ST. LOUIS – A new drug therapy has been administered at SSM Health hospitals since June 2021 that is proving to dissolve blood clots, particularly larger clots, in a shorter amount of time. Normally, ...
(HealthDay News) — New efforts to hasten treatment in both ambulances and emergency rooms appear to have significantly improved patients’ chances of survival and limited their long-term disability, ...
Every minute counts after the onset of a stroke. The more time that elapses before a patient receives an intravenous drug to help break up the clot that is blocking a blood vessel in the brain, the ...
SEATTLE--(BUSINESS WIRE)--According to Coherent Market Insights, the global tissue plasminogen activator market is estimated to be valued at US$ 2,455.4 million in 2020 and is expected to exhibit a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback